NCT01907308View on ClinicalTrials.gov

Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2014

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Urothelial Carcinoma
Interventions
DRUG

AMG 386

Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.

DRUG

Docetaxel

Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

University of Colorado, Denver

OTHER

NCT01907308 - Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma | Biotech Hunter | Biotech Hunter